Page 641 - Multidisipliner Covid 19

Psikiyatri Aç›s›ndan COVID-19

schizophreniaandmooddisorders. J ClinPsychiatry2016;77(5):573-579.
47. LandmarkCJ , Henning O, Johannessen SI.Proconvulsanteffects of anti-
depressants — What is thecurrentevidence? EpilepsyBehav. 2016; 61:
287-291.
48. Zambrelli E, Canevini M, Gambini O, D’AgostinoA. Deliriumandsleep
disturbances in COVID–19: a possible role for melatonin in hospitalized
patients?SleepMed. 2020; 70:111.
49. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, O’Meara MJ,
et al.A SARS-CoV-2-Human Protein-ProteinInteractionMapRevealsDrug
TargetsandPotentialDrug-Repurposing.Nature 2020; https://doi.
org/10.1038/s41586-020-2286-9.
50. Rosen DA,Seki SM,Fernández-Castañeda A,Beiter RM,Eccles JD,Woodfolk
JA,et al.Modulation of the sigma-1 receptor–IRE1 pathway is beneficial
in preclinicalmodels of inflammationandsepsis. SciTranslMed. 2019;
11(78):eaau5266.
51. Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al.COVID-19: Melatonin
as a potentialadjuvanttreatment. Life Sci.2020; https://doi.org/
10.1016/j.lfs.2020.117583.
52. Liu S, Yang L, Zhang C, et al. Online mentalhealthservices in China
duringthe COVID-19 outbreak. LancetPsychiatry. 2020;7(4):e17–e18.

640